Thomas DY - Search Results

1

The NSAID glafenine rescues class 2 CFTR mutants via cyclooxygenase 2 inhibition of the arachidonic acid pathway.

Carlile GW, Yang Q, Matthes E, Liao J, Birault V, Sneddon HF, Poole DL, Hall CJ, Hanrahan JW, Thomas DY. Carlile GW, et al. Among authors: thomas dy. Sci Rep. 2022 Mar 17;12(1):4595. doi: 10.1038/s41598-022-08661-8. Sci Rep. 2022. PMID: 35302062 Free PMC article.

2

Novel pharmacological strategies to treat cystic fibrosis.

Hanrahan JW, Sampson HM, Thomas DY. Hanrahan JW, et al. Among authors: thomas dy. Trends Pharmacol Sci. 2013 Feb;34(2):119-25. doi: 10.1016/j.tips.2012.11.006. Trends Pharmacol Sci. 2013. PMID: 23380248 Review.

3

Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.

Birault V, Solari R, Hanrahan J, Thomas DY. Birault V, et al. Among authors: thomas dy. Curr Opin Chem Biol. 2013 Jun;17(3):353-60. doi: 10.1016/j.cbpa.2013.04.020. Epub 2013 May 24. Curr Opin Chem Biol. 2013. PMID: 23711435 Review.

4

Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking.

Carlile GW, Robert R, Goepp J, Matthes E, Liao J, Kus B, Macknight SD, Rotin D, Hanrahan JW, Thomas DY. Carlile GW, et al. Among authors: thomas dy. J Cyst Fibros. 2015 Jan;14(1):16-25. doi: 10.1016/j.jcf.2014.06.001. Epub 2014 Jun 25. J Cyst Fibros. 2015. PMID: 24974227 Free article.

5

Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).

Matthes E, Goepp J, Carlile GW, Luo Y, Dejgaard K, Billet A, Robert R, Thomas DY, Hanrahan JW. Matthes E, et al. Among authors: thomas dy. Br J Pharmacol. 2016 Feb;173(3):459-70. doi: 10.1111/bph.13365. Epub 2016 Jan 13. Br J Pharmacol. 2016. PMID: 26492939 Free PMC article.

6

Corrector combination therapies for F508del-CFTR.

Hanrahan JW, Matthes E, Carlile G, Thomas DY. Hanrahan JW, et al. Among authors: thomas dy. Curr Opin Pharmacol. 2017 Jun;34:105-111. doi: 10.1016/j.coph.2017.09.016. Epub 2017 Nov 5. Curr Opin Pharmacol. 2017. PMID: 29080476 Review.

7

A novel triple combination of pharmacological chaperones improves F508del-CFTR correction.

Carlile GW, Yang Q, Matthes E, Liao J, Radinovic S, Miyamoto C, Robert R, Hanrahan JW, Thomas DY. Carlile GW, et al. Among authors: thomas dy. Sci Rep. 2018 Jul 30;8(1):11404. doi: 10.1038/s41598-018-29276-y. Sci Rep. 2018. PMID: 30061653 Free PMC article.

8

Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.

Hanrahan JW, Sato Y, Carlile GW, Jansen G, Young JC, Thomas DY. Hanrahan JW, et al. Among authors: thomas dy. Expert Opin Ther Targets. 2019 Aug;23(8):711-724. doi: 10.1080/14728222.2019.1628948. Epub 2019 Jun 9. Expert Opin Ther Targets. 2019. PMID: 31169041 Review.

9

The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del-CFTR.

Sato Y, Thomas DY, Hanrahan JW. Sato Y, et al. Among authors: thomas dy. J Biol Chem. 2019 Nov 29;294(48):18269-18284. doi: 10.1074/jbc.RA119.010192. Epub 2019 Oct 23. J Biol Chem. 2019. PMID: 31645438 Free PMC article.

10

The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants.

Turner MJ, Luo Y, Thomas DY, Hanrahan JW. Turner MJ, et al. Among authors: thomas dy. Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L908-L920. doi: 10.1152/ajplung.00285.2019. Epub 2020 Mar 11. Am J Physiol Lung Cell Mol Physiol. 2020. PMID: 32159371 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

247 results

Search Page

Filters